SERES Defense World / May 4, 2022
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
SERES News
SERES Defense World / May 4, 2022
Seres Therapeutics Misses Q1 EPS by 9c
Seres Therapeutics Misses Q1 EPS by 9c By Investing.com
Defense World
SERES Defense World / May 4, 2022
Wall Street analysts predict that Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Rating) will post $7.11 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Seres Therapeutics’ earnings. The highest sales estimate is $9.70 million and the lowest is
Defense World
SERES Defense World / May 4, 2022
In its extensive Global Microbiome Drugs Market from 2022 to 2028 research, MarketsandResearch.biz o
SERES Defense World / May 4, 2022
Seres Therapeutics (NASDAQ:MCRB – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platfor…
Defense World
SERES Queen Anne and Mangolia News / May 3, 2022
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here’s what investors need to know before the announcement. Analysts estimate that Seres Therapeutics will report an earnings per share (EPS) of $-0.52.
Preview: Seres Therapeutics's Earnings
Queen Anne and Mangolia News
SERES Queen Anne and Mangolia News / May 3, 2022
The Global Microbiome Drugs Market from 2022 to 2028 worldwide study paper, which Market Research Pl
SERES Defense World / May 2, 2022
Wall Street brokerages expect that Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) will report earnings of ($0.56) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Seres Therapeutics’ earnings, with the highest EPS estimate coming in a…
SERES Defense World / May 2, 2022
Global Online Water Quality Analyzer Market from 2022 to 2028 is a new storehouse of the MarketQuest
SERES Defense World / May 2, 2022
Equities research analysts predict that Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) will post earnings per share of ($0.56) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Seres Therapeutics’ earnings, with estimates ranging from (…
SERES Defense World / May 2, 2022
Let’s plot the history of the future.
Defense World
SERES Defense World / May 2, 2022
Equities research analysts forecast that Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) will report earnings of ($0.56) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Seres Therapeutics’ earnings, with the lowest EPS est…
SERES Defense World / May 2, 2022
Brokerages predict that Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) will report earnings per share of ($0.56) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Seres Therapeutics’ earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.61). Se…
SERES CarNewsChina.com / May 1, 2022
Story of how the Zhang family turned a small spring factory into the large Sokon Industry Group, making cars with Dongfeng and Huawei.
The Big Read – Dongfeng (6/6) – Sokon, a family business
CarNewsChina.com
SERES MarketBeat.com / Apr 30, 2022
Seres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Wednesday, May 4, Zacks reports.
SERES Benzinga / Apr 29, 2022
Seres Therapeutics (NASDAQ:MCRB – Get Rating) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 4th. Analysts expect Seres Therapeutics to post earnings of ($0.56) per share for the quarter. Seres Therapeutics (NASDAQ:MCRB – Get Rating) last posted its quarterl…
SERES Benzinga / Apr 29, 2022
Seres Therapeutics (NASDAQ:MCRB) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
SERES GuruFocus.com / Apr 28, 2022
Seres Therapeutics, Inc. (NASDAQ:MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first
SERES GuruFocus.com / Apr 28, 2022
The SUV is expected to be the first production vehicle to be marketed under the premium EV brand AITO, which was recently launched by Seres. Read more in the article.
Huawei underlines its ambitions to develop their own EV
GuruFocus.com
SERES GuruFocus.com / Apr 28, 2022